Full Text View
Tabular View
No Study Results Posted
Related Studies
Primary Progesterone Therapy for Operable Breast Cancer
This study is ongoing, but not recruiting participants.
Study NCT00123669   Information provided by Tata Memorial Hospital
First Received: July 21, 2005   Last Updated: August 1, 2005   History of Changes

July 21, 2005
August 1, 2005
October 1997
 
To test the effect of primary progesterone in operable breast cancer on overall and disease free survival at 5 years
To test the effect of primary progesterone in operable breast cancer on overall and disease free survival at 5 years.
Complete list of historical versions of study NCT00123669 on ClinicalTrials.gov Archive Site
 
 
 
Primary Progesterone Therapy for Operable Breast Cancer
The Primary Progesterone Therapy for Operable Breast Cancer : A Randomized Controlled Trial

The purpose of this study is to test the effect of primary progesterone on overall and disease free survival in women with operable breast cancer. The study addresses two issues related to breast cancer surgery:

  • Circulating progesterone at the time of surgery might counteract the detrimental effect of estrogen on survival of women with operable breast cancer.
  • Events at the time of surgery may have an impact on the natural history of breast cancer

This protocol addresses the issue of pre-operative hormone manipulation in women with operable breast cancer. The study has been designed after careful review of literature to assess the effect of unopposed oestrogen at the time of surgery and collect evidence that events at the time of surgery may have impact on the long-term survival of breast cancer patients. The meta-analysis of 37 studies on timing of surgery during the menstrual cycle showed a 15% + 3 improvement in survival for women who had undergone surgery during the luteal phase of their menstrual cycle. Three of the 37 studies where progesterone levels were estimated at the time of surgery showed 52% + 26 improvement in survival when circulating progesterone were > 1.5 ng/ml. The study aims to produce luteal milieu by injecting Hydroxy- progesterone 500 mg IM at the time of surgery. The timing of administration of progesterone in the neo-adjuvant setting is decided after collating data from large data-bases and randomised trials of screening suggesting that events at the time of surgery may alter the behavior of micro-metastases.

Phase III
Interventional
Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Breast Neoplasms
Drug: Depot preparation of Hydroxyprogesterone hexanoate 500mg
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Active, not recruiting
1000
 
 

Inclusion Criteria:

  • Unilateral operable palpable breast cancer

Exclusion Criteria:

  • Previous history of excision biopsy of the primary tumour
  • History of other epithelial/mesenchymal malignant tumours except basal cell carcinoma/squamous cell carcinoma (BCC/SCC) of skin
Female
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
India
 
NCT00123669
 
No. SP/SO/B29/2000
Tata Memorial Hospital
Ministry of Science and Technology, India
Principal Investigator: Rajendra A Badwe, M.S. Professor & Head, Department of Surgical Oncology, Chief Breast Unit
Tata Memorial Hospital
April 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP